Palmitoyl Tripeptide-1

Skin / Anti-Aging

Also known as: Pal-GHK, Biopeptide CL, Palmitoyl Oligopeptide

Signal Peptides (Cosmetic)Research phase: Extensive cosmetic clinical dataRegulatory: Cosmetic ingredient. Not a drug.

Mechanism

A lipid-attached version of the GHK peptide (the same one used in GHK-Cu) designed for topical skin application. It penetrates the skin to stimulate collagen production and tissue repair. Often combined with Palmitoyl Tetrapeptide-7 in products marketed as Matrixyl 3000.

Technical detail

Palmitoyl conjugate of Gly-His-Lys (GHK) tripeptide. Palmitic acid moiety enhances stratum corneum penetration and cell membrane interaction. Activates TGF-beta and MMP regulatory pathways similar to free GHK. Stimulates collagen I/III synthesis, fibronectin production, and glycosaminoglycan deposition. When combined with Palmitoyl Tetrapeptide-7 (an IKK-inhibiting anti-inflammatory peptide), marketed as Matrixyl 3000 — clinical studies show synergistic wrinkle reduction up to 45% over 2 months (Sederma clinical data).

Effects

## Integumentary System — Collagen Stimulation and Tissue Remodeling [Tier 2 — Moderate Human Data] Palmitoyl-Tripeptide-1 (Pal-GHK) is a lipopeptide derivative of the naturally occurring GHK (Gly-His-Lys) tripeptide, modified with a palmitic acid tail for enhanced skin penetration. GHK is a well-characterized matrikine — a collagen fragment released during tissue remodeling that signals fibroblasts to produce new ECM components. Pal-GHK stimulates collagen I synthesis (up to 350% increase in vitro), glycosaminoglycan production (including hyaluronic acid and dermatan sulfate), and decorin (a proteoglycan that organizes collagen fibrils into proper structural bundles). Unlike peptides that simply increase collagen quantity, GHK-based peptides improve collagen QUALITY — the fibrils are better organized and more resistant to MMP degradation. ## Wound Healing [Tier 2 — Human and Animal Data] The parent peptide GHK has a strong wound healing evidence base (it is the copper-binding domain of GHK-Cu). Pal-GHK retains this wound-healing signaling capacity, promoting fibroblast migration, angiogenesis, and coordinated tissue repair. The palmitoyl modification improves topical delivery but limits the copper-binding that characterizes GHK-Cu. ## Anti-Inflammatory Effects [Tier 2 — In Vitro/Clinical Data] Pal-GHK reduces TGF-beta-mediated fibrosis signaling at high levels while maintaining pro-collagen signaling at physiological levels. It also reduces expression of several pro-inflammatory cytokines (IL-6, TNF-alpha) in UV-irradiated keratinocytes.

Practitioner Guide

## Practical Formulation Guide ### Relationship to GHK-Cu Pal-GHK (Palmitoyl-Tripeptide-1) and GHK-Cu are related but different: - **GHK-Cu:** The copper-complexed form. Used as a standalone active (typically in serums at 0.5-2% concentration). The copper is essential for some of GHK-Cu's wound healing and antioxidant effects. - **Pal-GHK:** The palmitoylated form WITHOUT copper. Optimized for cosmetic formulation — better penetration, better stability, compatible with more ingredients (copper-free means no oxidation or compatibility issues with vitamin C or acids). ### Effective Concentrations - **As part of Matrixyl 3000:** 3-8% of commercial solution. - **As standalone:** 50-200 ppm active peptide. ### Formulation Considerations - **pH:** Stable at pH 5.0-7.0. - **Compatibility:** Compatible with virtually all cosmetic ingredients. Unlike GHK-Cu, the copper-free Pal-GHK does not oxidize or interfere with L-ascorbic acid, retinol, or other actives. - **Key advantage over GHK-Cu for formulation:** No color change (GHK-Cu is blue), no copper-mediated oxidation of other ingredients, broader compatibility, better shelf stability. ### Where It Fits in a Multi-Peptide Protocol Pal-GHK is the "collagen remodeling" peptide. Combine with: - **Matrixyl (Pal-KTTKS):** Different collagen-stimulation pathway — additive effect. - **Pal-Tetrapeptide-7:** The Matrixyl 3000 pairing — collagen stimulation + anti-inflammation. - **Argireline:** Different mechanism (expression line relaxation vs. collagen stimulation) — complementary. ### Realistic Expectations - **4 weeks:** Improved skin texture and hydration. Early collagen stimulation not yet clinically visible. - **8 weeks:** Measurable improvement in skin firmness and elasticity (cutometry). Fine lines begin to soften. - **12-24 weeks:** Optimal results. Improved dermal density on ultrasound. Skin appears fuller and more resilient. Comparable to Matrixyl efficacy for collagen endpoints.

Dosing Protocols

skin_rejuvenationbasic tier
Frequency
2x daily
Timing
Morning and evening after cleansing; apply to face and neck before moisturizer; follow with SPF in the morning
Route
topical
Cycle
8-52 weeks

Palmitoyl Tripeptide-1 (GHK fragment with palmitoyl group) acts as a matrikine — a peptide fragment from extracellular matrix degradation that signals fibroblasts to produce new collagen and elastin. Usually combined with Palmitoyl Tetrapeptide-7 as Matrixyl 3000, which adds anti-inflammatory activity via IL-6 inhibition. At 50-200ppm in serum formulation, clinical studies show synergistic wrinkle reduction and skin firmness improvement. Topical only — not injectable. Continuous use.

Contraindications & Cautions

  • hard stopUnder 18 years of age
    Cosmetic peptide protocols not designed for pediatric use.
    Action: Do not provide to individuals under 18.
  • cautionAllergy to cosmetic ingredients
    Contact dermatitis or allergic reactions possible. Palmitoyl group may cause sensitization in some individuals.
    Action: Perform patch test 24-48 hours before full application. Discontinue if irritation occurs.
  • cautionOpen wounds or broken skin
    Cosmetic peptides should only be applied to intact skin.
    Action: Do not apply to broken skin, open wounds, or active dermatitis.
  • cautionPregnancy or breastfeeding
    Limited safety data for topical cosmetic peptides during pregnancy and lactation.
    Action: Consult physician before use during pregnancy or breastfeeding.

Evidence

  • Biologically active peptides: from laboratory to the consumer via cosmetics

    Lintner K, Peschard O (2000) — International Journal of Cosmetic Science — PMID: 18503472

    Palmitoyl tripeptide-1 (Pal-GHK) is a lipidated derivative of the GHK sequence that enhances skin penetration. Stimulates collagen synthesis, glycosaminoglycan production, and wound healing through activation of TGF-beta signaling. Clinical studies showed improvements in skin firmness, wrinkle reduction, and overall skin appearance over 2-4 months of topical use. Often combined with palmitoyl tetrapeptide-7 (Matrixyl 3000).

    emerging

Research Summary

## Tier 1 — Strong Clinical Evidence - GHK tripeptide mechanism is extensively validated in the scientific literature (Pickart et al., extensive publication history) - Pal-GHK as a component of Matrixyl 3000 has multiple positive clinical studies ## Tier 2 — Moderate Evidence - Clinical studies showing improved wrinkle depth, skin firmness, and dermal density after 8-12 weeks of topical application - In vitro data: 350% increase in collagen I synthesis, increased GAG production, improved collagen fibril organization - Comparative efficacy with Matrixyl (original) — similar endpoint improvement via different signaling pathways ## Tier 3 — Preclinical/Theoretical - May have superior wound healing properties compared to non-GHK cosmetic peptides - Potential for synergy with GHK-Cu (topical Pal-GHK for daily use + periodic GHK-Cu serum for intensive treatment) - Application in scar remodeling — GHK pathway promotes organized collagen vs. scar collagen (in vitro data)